載入...
Doravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations
Doravirine (DOR), which is currently in a phase 3 clinical trial, is a novel human immunodeficiency type 1 virus (HIV-1) nonnucleoside reverse transcriptase inhibitor (NNRTI). DOR exhibits potent antiviral activity against wild-type virus and K103N, Y181C, and K103N/Y181C mutant viruses, with 50% in...
Na minha lista:
| 發表在: | Antimicrob Agents Chemother |
|---|---|
| Main Authors: | , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
American Society for Microbiology
2016
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4808216/ https://ncbi.nlm.nih.gov/pubmed/26833152 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02650-15 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|